{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T23:21:22Z","timestamp":1782429682557,"version":"3.54.5"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.adro.2020.11.008","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T12:59:29Z","timestamp":1606395569000},"page":"100623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Lutetium Lu-177 Dotatate Flare Reaction"],"prefix":"10.1016","volume":"6","author":[{"given":"Andrew L.","family":"Salner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bette","family":"Blankenship","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Dunnack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helaine","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2020.11.008_bib1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.soc.2019.11.005","article-title":"Overview and current status of peptide receptor radionuclide therapy","volume":"29","author":"Bushnell","year":"2020","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.adro.2020.11.008_bib2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","article-title":"Carcinoid tumors","volume":"340","author":"Kulke","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2020.11.008_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2020.11.008_bib4","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.adro.2020.11.008_bib5","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 Trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.11.008_bib6","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2967\/jnumed.117.189712","article-title":"Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: Incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors","volume":"59","author":"Bergsma","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.adro.2020.11.008_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: The value and limitations of clinical factors","volume":"42","author":"Bodei","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.adro.2020.11.008_bib8","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","article-title":"Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.adro.2020.11.008_bib9","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1097\/RLU.0000000000002118","article-title":"Acute pancreatitis following peptide receptor radionuclide therapy: An unusual adverse event","volume":"43","author":"Karfis","year":"2018","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.adro.2020.11.008_bib10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00259-013-2601-x","article-title":"Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate","volume":"41","author":"Sabet","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.adro.2020.11.008_bib11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2004.12.016","article-title":"Pain flare following external beam radiotherapy and meaningful change in pain scores in the treatment of bone metastases","volume":"75","author":"Chow","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2020.11.008_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijrobp.2008.10.044","article-title":"Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: Results from three Canadian cancer centers","volume":"75","author":"Hird","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.11.008_bib13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/CAD.0000000000000814","article-title":"Tumour flare reaction in cancer treatments: A comprehensive literature review","volume":"30","author":"Taleb","year":"2019","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.adro.2020.11.008_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.clon.2008.12.010","article-title":"Dexamethasone for the prophylaxis of radiation-induced pain flare after palliative radiotherapy for symptomatic bone metastases: A phase II study","volume":"21","author":"Hird","year":"2009","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.adro.2020.11.008_bib15","first-page":"643","article-title":"Dexamethasone for the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: A pilot study","volume":"15","author":"Chow","year":"2007","journal-title":"Support Care Cancer"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109420303535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109420303535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:38:41Z","timestamp":1762529921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109420303535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2452109420303535"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2020.11.008","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lutetium Lu-177 Dotatate Flare Reaction","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2020.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100623"}}